Invion Share Price and Company Fundamentals



Price
$0.009
Change
-0.001 (-10.000%)
52 week
0.007 - 0.013

Last traded: Today at 5:31 AM

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.

Key Metrics

PE ratio

-

PB ratio

9.00

Dividend yield

Beta

1.74

Market cap

$49.84M

Enterprise value

$43.78M

Company profile

Primary activitiesClinical-stage pharmaceutical drug development
Industry / SectorDrug Manufacturers—Specialty & Generic / Healthcare
Websitehttp://www.inviongroup.com
Mailing address692 High Street East Kew Melbourne VIC 3102 Australia
Phone / Fax61 3 8618 6843 /
Share registryLINK MARKET SERVICES LIMITED

Annual reports

Published onReport
26 Aug 2020Appendix 4E and Annual Report

Dividends

Invion does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Invion.

NameTitleAgeTotal Pay
Mr. Thian ChewInterim CEO & Exec. Chairman194.11k
Ms. Melanie Jaye Leydin C.A., B.Bus, CACFO & Company Sec.47
Dr. Dean NaylorHead of Intellectual Property Devel.

Profitability and management effectiveness

Profit margin

-21.82%

Operating margin

-27.34%

Return on assets

-8.69%

Return on equity

-11.97%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Invion is 49.84M and its enterprise value is 43.78M. The enterprise value to revenue ratio of IVX is 15.27.

The IVX's stocks Beta value is 1.74 making it 74% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Invion (IVX)

Invion (ASX:IVX) Frequently Asked Questions

1. What is Invion's Stock Symbol?

Invion trades on ASX under the ticker symbol "IVX".

2. What is Invion's stock price today?

One share of IVX stock can currently be purchased for approximately $0.009.

3. How can I contact Invion?

Invion's mailing address is 692 High Street East Kew Melbourne VIC 3102 Australia. The company can be reached via phone at 61 3 8618 6843.

4. What is Invion's official website?

The official website of Invion is http://www.inviongroup.com.

5. Which share registry manages Invion's stock?

Invion's stock is managed by LINK MARKET SERVICES LIMITED.